Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Sponsor: Liquidia Technologies, Inc.
A PHASE3 clinical study on Primary Pulmonary Hypertension, this trial is ongoing. The trial is conducted by Liquidia Technologies, Inc. and has accumulated 9 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Active Not Recruiting PHASE3
Status: Unknown → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Sep 2021 — May 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Oct 2019 — May 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jul 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Liquidia Technologies, Inc.
- Nuventra, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .